Business Description
ALX Oncology Holdings Inc
NAICS : 541714
SIC : 2834
Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 291.5 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 18.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -100 | |||||
| 3-Year EBITDA Growth Rate | -50.8 | |||||
| 3-Year EPS without NRI Growth Rate | -19.5 | |||||
| 3-Year FCF Growth Rate | -42.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.12 | |||||
| 9-Day RSI | 28.45 | |||||
| 14-Day RSI | 33.06 | |||||
| 6-1 Month Momentum % | -23.08 | |||||
| 12-1 Month Momentum % | -82.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.23 | |||||
| Quick Ratio | 13.23 | |||||
| Cash Ratio | 13.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.46 | |||||
| ROA % | -28.9 | |||||
| ROIC % | -456.77 | |||||
| ROC (Joel Greenblatt) % | -2874.66 | |||||
| ROCE % | -30.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.23 | |||||
| Price-to-Tangible-Book | 1.23 | |||||
| EV-to-EBIT | -0.7 | |||||
| EV-to-Forward-EBIT | -0.52 | |||||
| EV-to-EBITDA | -0.7 | |||||
| EV-to-Forward-EBITDA | -0.52 | |||||
| EV-to-FCF | -0.91 | |||||
| Price-to-Net-Current-Asset-Value | 1.36 | |||||
| Price-to-Net-Cash | 1.38 | |||||
| Earnings Yield (Greenblatt) % | -142.86 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALXO
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -2.72 | ||
| Beta | 0 | ||
| Volatility % | 87.21 | ||
| 14-Day RSI | 33.06 | ||
| 14-Day ATR ($) | 0.86751 | ||
| 20-Day SMA ($) | 11.3885 | ||
| 12-1 Month Momentum % | -82.4 | ||
| 52-Week Range ($) | 5.82 - 76.15 | ||
| Shares Outstanding (Mil) | 40.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ALX Oncology Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
ALX Oncology Holdings Inc Analysis
Share your researchHeadlines
See More
No news.